



ALZ-801 Shows Sustained Biomarker Improvements in Early Alzheimer's Disease

Peer-reviewed data showed that oral valiltramiprosate (ALZ-801) produced sustained reductions in key Alzheimer's biomarkers that correlated with cognitive, functional, and brain-volume outcomes in APOE4 carriers with early disease, supporting continued Phase 3 development.

[Read More](#)

ACI-19764 Shows Positive Phase 1 Data in Neuroinflammation

Preliminary Phase 1 data showed ACI-19764 was safe and well tolerated, with evidence of brain penetration. A Phase 1b cohort is now underway to evaluate anti-inflammatory activity, with initial results expected by year-end.

[Press Release](#)

LEQEMBI IQLIK Now Available for Early Alzheimer's Disease

LEQEMBI IQLIK, a once-weekly subcutaneous autoinjector, is now available in the U.S. for initiation and maintenance therapy in adults with early Alzheimer's disease, offering an at-home alternative to IV administration.

[More Details](#)

Masupirdine Completes Phase 3 Enrollment for Alzheimer's-Related Agitation

Suven Life Sciences completed enrollment in its global Phase 3 study of masupirdine for agitation associated with Alzheimer's dementia, with 424 patients randomized. Topline results are expected by May 2027.

[Learn More](#)

BioVie Advances Phase 3 Development of Bezisterim in Parkinson's Disease

BioVie is working with the FDA to align on the Phase 3 trial design for bezisterim in early-stage Parkinson's disease, with formal feedback expected before year-end.

[Learn More](#)

This month's updates feature new data and clinical milestones across Alzheimer's and neuroscience, including advances in treatment, late-stage development, and neuroinflammation.

CPE Spotlight

A New CPE Offering!


Case-Based Product Theater

What if your next product theater felt more like a clinical discussion than a presentation?

Our Case-Based Product Theater offering brings:

- Realistic patient scenarios that put clinical data into context
- Interactive discussion that engages HCPs in treatment decisions
- A practical approach that connects evidence to everyday patient care

Patient-First Approach



Explore Our Website

Our new website offers a closer look at how CPE connects science, strategy, and education to support meaningful healthcare engagement.

[Visit us at cpeducate.com](#)

Below is a list of CPE's core service offerings for clients across marketing and medical affairs. While these reflect our core capabilities, our team regularly customizes solutions to meet evolving client needs.

Medical Affairs

Asynchronous Engagements
KOL Identification & Contracting
MOA Visualization
MSL Training
Patient Education
Poster Presentations
Scientific Platform Development

Medical Affairs + Marketing

Advisory Boards
(Virtual or In-Person)
Conference Planning
Content Development
Core Slide Decks
KOL Engagements
Publications

Marketing

Branding & Visual Aids
Healthcare Event Production Management
Launch Preparation
Product Theater Planning & Logistics
Speaker Bureau Services
Speaker Training
Technical Productions

CPE's **Case-Based Product Theater** offering brings evidence to life through realistic patient scenarios, while our **At the Table™** and **Dedicated KOL Brand Ambassador** programs create new opportunities for meaningful HCP and KOL engagement.

Ready to bring your next program to life? Reply to this email and let's talk.

With appreciation,

Allison Goldberg, MPA
Associate Vice President
CPE Communications
Cell: 917-509-9583
agoldberg@cpeducate.com

When you're ready to explore how the CPE Communications Team can support your company, contact Allison at agoldberg@cpeducate.com